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Abstract
Background: Niemann–Pick disease type C is a fatal and progressive neurodegenerative disorder characterized by
the accumulation of unesterified cholesterol in late endosomes and lysosomes. We sought to develop new
therapeutics for this disorder by harnessing the body’s endogenous cholesterol scavenging particle, high-density
lipoprotein (HDL).
Methods: Here we design, optimize, and define the mechanism of action of synthetic HDL (sHDL) nanoparticles.
Results: We demonstrate a dose-dependent rescue of cholesterol storage that is sensitive to sHDL lipid and
peptide composition, enabling the identification of compounds with a range of therapeutic potency. Peripheral
administration of sHDL to Npc1 I1061T homozygous mice mobilizes cholesterol, reduces serum bilirubin, reduces
liver macrophage size, and corrects body weight deficits. Additionally, a single intraventricular injection into adult
Npc1 I1061T brains significantly reduces cholesterol storage in Purkinje neurons. Since endogenous HDL is also a
carrier of sphingomyelin, we tested the same sHDL formulation in the sphingomyelin storage disease Niemann–
Pick type A. Utilizing stimulated Raman scattering microscopy to detect endogenous unlabeled lipids, we show
significant rescue of Niemann–Pick type A lipid storage.
Conclusions: Together, our data establish that sHDL nanoparticles are a potential new therapeutic avenue for
Niemann–Pick diseases.
Keywords: Niemann–Pick C, NPC1, HDL, SRS, Niemann–Pick A
Background
Niemann–Pick disease type C is a fatal lysosomal storage
disorder that causes progressive neurodegeneration along
with visceral organ involvement. Symptom onset and dis-
ease severity are variable, but patients commonly develop
hepatosplenomegaly, cognitive decline, and seizures, cul-
minating in death in the second or third decades of life [1,
2]. Niemann–Pick C patients have loss-of-function
mutations in the NPC2 (~ 5%) or, more commonly, the
NPC1 (~ 95%) protein. In the late endosome/lysosomal
compartment (LE/Lys), LDL-derived unesterified choles-
terol is bound by NPC2 and transferred to the transmem-
brane NPC1 protein [3, 4]. Using a poorly defined
mechanism, NPC1 exports unesterified cholesterol from
LE/Lys. Unesterified cholesterol then moves to other sites
within the cell where it alters membrane dynamics or is uti-
lized for steroid production [4]. In patients with Niemann–
Pick C, mutations in NPC1/NPC2 prevent intracellular
lipid trafficking and cause characteristic cholesterol accu-
mulation [5]. A biochemically similar lipid storage disease
arises from mutations in the gene encoding the lysosomal
enzyme acid sphingomyelinase. Deficiency of enzyme
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activity causes Niemann–Pick disease types A and B, in
which the storage of sphingolipids and cholesterol in LE/
Lys leads to hepatosplenomegaly and varying degrees of
neurodegeneration [6].
Endogenous mechanisms to maintain cellular cholesterol
homeostasis include the removal of excess cholesterol by
high-density lipoprotein (HDL) particles. Cholesterol is
effluxed from peripheral cells by nascent HDL particles
and esterified in plasma. Mature HDLs then travel to the
liver where cholesterol is eliminated in the bile [7]. Recent
work has taken advantage of endogenous HDL function for
the development of synthetic HDL (sHDL) nanoparticles as
potential therapeutics for cardiovascular diseases [8–11].
These nanoparticles are composed of the HDL protein
apolipoprotein A-1 (ApoA1) or ApoA1 mimetic peptides
surrounding a lipid bilayer to form 10–12-nm diameter dis-
coidal lipoprotein particles [12, 13]. Chemical synthesis of
sHDL permits modifications that alter lipid and ApoA1
peptide composition and thereby impact potency, pharma-
cokinetics, and safety [14–17]. sHDL nanoparticles were ini-
tially designed for removal of cholesterol from lipid-laden
atherosclerotic plaques. In clinical trials involving ~ 2000
cardiovascular disease patients, sHDL was safe and well-
tolerated [10, 11, 18–21], and a large phase III clinical trial
in 17,400 patients is currently ongoing (https://clinicaltrials.
gov/ct2/show/NCT03473223).
Here, we developed and optimized a sHDL nanoparticle
which significantly reduces the accumulated cholesterol in
Niemann–Pick type C cells. The sHDL contains a 37-
amino acid ApoA1 mimetic peptide, termed 5A, and
sphingomyelin (SM). 5A-SM sHDL at 1:1.15 (wt/wt) pep-
tide to lipid ratio is safe in primates, and with established
sterile manufacturing, this sHDL is well positioned for
rapid clinical translation [22, 23]. We show that 5A-SM
sHDLs are non-toxic and effective at reducing cholesterol
storage in Niemann–Pick C patient fibroblasts and brain
slice cultures from Npc1 mutant mice. We establish that
5A-SM requires the ATP-binding cassette transporter 1
(ABCA1) to efflux stored cholesterol. In vivo studies using
Npc1 mutant mice show evidence of target engagement
and rescue of peripheral phenotypes and neuronal choles-
terol storage. Furthermore, we show that 5A-SM also
rescues sphingomyelin storage in Niemann–Pick type A
fibroblasts. Together, these studies provide proof-of-
concept data to support the therapeutic potential of sHDL
for the Niemann–Pick diseases.
Methods
Mice
All Npc1-I1061T mice [24] were backcrossed to C57BL/6
(≥ 10 generations). Approximately equal numbers of males
and females were used for all experiments, and littermates
were used when available. Mice were randomly assigned to
vehicle or experimental groups. All procedures involving
mice were approved by the University of Michigan Com-
mittee on Use and Care of Animals (PRO00008133) and
conducted in accordance with institutional and federal
guidelines.
Reagents
2-Hydroxypropyl-β-cyclodextrin (H-107) and amiloride
(A7410) were from Sigma. EndoH (P0702) and PNGaseF
(P0704) were from New England Biolabs. Dynasore (14061)
was from Cayman Chemical; Human HDL (J64903) and
acetylated LDL (J65029) were from Alfa Aesar. 5A peptide
(DWLKAFYDKVAEKLKEAF-P-DWAKAAYDKAAEKAK
EAA, 4078379) was from Bachem Americas (Torrance,
CA). 22A peptide (PVLDLFRELLNELLEALKQKLK) was
synthesized by Genscript (Piscataway, NJ). Lipids including
egg-sphingomyelin (SM, Coastome NM-10), 1,2-dimyris-
toyl-sn-glycero-3-phosphocholine (DMPC, Coastome MC-
4040), and 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocho-
line (POPC, Coastome MC-6081) were from NOF America
Corporation. 1,1′-Dioctadecyl-3,3,3′,3′-tetramethylindodica
rbocyanine, 4-chlorobenzenesulfonate salt (DiD, D7757)
and 4-(4-(dihexadecylamino)styryl)-N-methylpyridinium io
dide (DiA, D3883) were from Invitrogen. Cholesteryl [1,2,6,
7-3H(N)] linoleate (ART 1203) and sphingomyelin [choline
methyl-3H] were from American Radiolabeled Chemicals
(Saint Louis, MO). N-[6-[(7-Nitro-2-1,3-benxoxadiazol-4-
yl)amino]-sphingosine-1-phosphocholine (NBD-Sphingo-
myelin, 810218P) was from Avanti Polar Lipids (Alabaster,
AL).
Antibodies
(Antigen, dilution, vendor, cat. no.): NPC1, 1:500,
Abcam, ab134113; Actin, 1:4000, Sigma, A544; LAMP1,
1:100, Developmental Studies Hybridoma Bank Univer-
sity of Iowa, H4A3; Calbindin, 1:500–1:2000, Sigma,
02724; GFAP, 1:500, Dako, z0344; IBA1, 1:250, Abcam,
ab5076; NeuN, 1:500, Millipore, abn78; EEA1, 1:400,
Abcam, ab2900; F4/80, 1:400, abcam, ab6640.
sHDL synthesis
sHDL particles were prepared using a lyophilization
method where peptide (5A or 22A) and lipid (SM,
DMPC or POPC) were dissolved in acetic acid at 1:1.5
wt/wt ratio and then lyophilized together for 24 h. HDL
was fluorescently labeled by adding 4 μg DiD or DiA per
1 mg peptide directly to the acetic acid mixture of pep-
tide and SM. The resulting lyophilized dry pellet was re-
hydrated in PBS, pH 7.4, to a final peptide concentration
of 10 mg/mL, vortexed, and thermocycled 3× between
55 °C and room temperature to generate sHDL particles.
pH was adjusted to 7.4 and sHDLs were sterile filtered
using 0.22-μm Millipore filters. Labeling of 5A peptide
in sHDL (5A-SM-DiA) with AlexaFluor 647 dye was
performed using Invitrogen protein labeling kit
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(A20173). Purification of 5A-SM-DiA-Alexa647 post-
labeling was done on the size-exclusion column supplied
in the kit, and the final concentration of sHDL was de-
termined according to the manufacturer’s instructions
using plate reader measurements (SynergyTM NEO
HTS Multi-Mode Microplate Reader, Bio-Tek).
sHDL characterization
Fluorescently labeled sHDL particles were analyzed by
UPLC (Waters Aquity UPLC BEH125 sec 1.7 μm, 4.6 ×
150mm column) equipped with UV (220 nm) and fluores-
cence detectors (ex/em 644/665 nm DiD, 456/590 nm DiA,
650/665 nm AlexaFluor647). The hydrodynamic diameters
of sHDL were determined by dynamic light scattering on
Zetasizer Nano ZSP, Malvern Instruments (Westborough,
MA). The volume intensity average values were reported.
Transmission electron microscopy images were obtained
on an FEI Morgagni electron microscope run at 100 kV at
a magnification of 22,000× (2.1 Å/pixel) and then recorded
on a Gatan Orius charge-coupled device camera. sHDL
samples (3 μL of 2 μg/ml) were adsorbed for 1min to a
glow discharged 400-mesh copper grid covered with
carbon-coated collodion film (Structure Probe). The grids
were washed twice and then negatively stained in 0.07% ur-
anyl formate. 22A and 5A peptides, SM, POPC, and DMPC
lipids combined at 1:0.5, 1:1, and 1:2 wt/wt ratios were de-
scribed previously [14, 15].
Cells
Cell lines were obtained from the NIGMS Human Cell
Repository at the Coriell Institute for Medical Research.
GM08399 was used as a control (CTRL) cell line. Nie-
mann–Pick C cell lines with mutations in the NPC1
gene: GM18453 (I1061T/I1061T), GM17912 (P1007A/
T1036M), and GM03123 (I1061T/P237S); Niemann–
Pick A (NPA) cell line with mutation in the SMPD1
gene GM00112 (L302P/L302P). Cells were cultured in
MEM, PSG, and 20% FBS [25].
Treatments
Endocytosis inhibitors
Cells were pretreated with dynasore (80 μM) or amilor-
ide (1 mM) for 30 min. Cell culture media was replaced
with fresh media containing vehicle (saline), dynasore, or
amiloride along with 5A-SM-DiD for 2 h. ImageJ was
used to quantify DiD label intensity inside cells.
sHDL in cells
Cells were plated 24 h before treatment. At the start of
treatment, cell culture media was replaced with media
containing vehicle or sHDL. Culture media containing
vehicle or sHDL was refreshed after 24 h.
sHDL treatment of brain slices
Slices were treated with fresh particles/media daily at a
concentration of 5 mg/ml for a period of 4 days.
siRNA transfection
Predesigned ON-TARGETplus SMARTpools containing 4
individual siRNAs per target sequence (Dharmacon Non-
targeting SMARTpool D-001810-10-05, ABAC1 L-004128-
00, SR-B1 L-010592-00) were transfected using TransIT-
X2® (Mirus) reagent at t = 0 and t = 24 h. Imaging or RNA
analysis occurred 48 h after the first transfection [25].
Western blot
A bullet blender (Next Advance) was used to homogenize
cell lysates. Protein concentrations were normalized by
DC™-protein assay (Bio-Rad), and equal amounts of pro-
tein were loaded into 4–12% gradient SDS PAGE gels
(Invitrogen). After electrophoresis and transfer onto a
PVDF membrane, immunoreactivity was detected by ECL
(Thermo Scientific) and imaged using an iBright (Thermo
Fisher Scientific). ImageJ was used to quantify band inten-
sity [25]. For Endoglycosidase H assay, lysates were sepa-
rated into three reactions containing: negative control
(NT), EndoH (E) (NEB P0702L), or PNGaseF (P) (NEB
P0704L) [25]. After a 3-h incubation at 37 °C, samples
were loaded on SDS PAGE gels as indicated above.
Filipin staining
After treatment, cell membranes were labeled with
wheat germ agglutinin® (Thermo Fisher). Cells were
fixed in 4% PFA for 20 min, washed 3× in PBS, and 1×
in glycine. Unesterified cholesterol was labeled with fili-
pin labeling solution for 2 h. Filipin labeling solution:
10% FBS + 0.4% DMSO+ 0.03 mg/ml (tissue) or 0.1 mg/
ml (cells) filipin. Slides were washed 3× with PBS and
mounted with ProLong® Gold (Thermo Fisher) [25].
RT-qPCR
RNA was converted to cDNA using the High Capacity Re-
verse Transcription kit (Applied Biosystems 4368814).
Quantitative real-time PCR (RT-qPCR) was conducted in
technical triplicates using 15 ng cDNA, TaqMan™ probes
(Thermo Fisher) for human HMGCR (Hs 00168302),
HMGCS1 (Hs 00940429), ABCA1 (Hs 01059118), ABCG1
(Hs 00245154), LDLR (Hs 01092524), NPC1 (Hs 0026
4835), SCARB1 (SR-B1) (Hs 00969821), SREBF-2 (SREBP)
Hs 01081778, GAPDH (loading control) (4325792), and
mouse HMGCS (Mm 01304569). RT-qPCR was performed
using an ABI 7900HT Sequence Detection System and rela-
tive expression calculated by the 2−ΔΔCt method using SDS
software.
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Immunofluorescence staining
Cells were washed 3× with HBSS and fixed with 4% PFA
for 20min at room temperature. Cells were washed with
PBS and glycine before addition of blocking solution (0.02%
saponin, 10% normal goat serum (NGS), 1% BSA) for 1 h.
Slides were incubated with primary antibodies overnight at
4 °C, washed with PBS + 0.02% saponin, and incubated with
secondary antibody for 1 h [25]. Slides were mounted with
Vectashield + DAPI (Vector Laboratories).
For slice culture: slices were floated in HBSS+/+ in 6-
well plates containing Netwell™ Inserts (Corning). Samples
were fixed in 4% PFA and 0.1% Triton X-100 for 1 h,
rinsed 3× in PBS, then treated for 10min of 1.5 mg/ml
glycine. After three washes in PBS, slices were blocked in
PBS containing 5% NGS for 1 h at room temperature.
Slices were labeled with primary antibody (diluted in
blocking) overnight. The following day, slices were washed
3× in PBS and labeled with Alexa conjugated secondary
(1:500) for 1 h. After 3 washes in PBS, slices were stained
with filipin labeling solution for 2 h, washed 3× with PBS,
and mounted in ProLong Gold (ThermoFisher) and im-
aged by confocal microscopy. Calbindin was used to out-
line Purkinje cells, and filipin intensity was calculated
using ImageJ.
Preparation of cerebellar organotypic slice cultures
Cerebellar organotypic slice cultures were prepared using
30- μm thickness sagittal brain slices [26]. Four slices per
brain were used in each set of experiments, split evenly
between control and experimental medium. Two slices
were placed together on a cell culture insert (Millipore;
0.4-μm pore size, 30mm diameter) which contained 1.2-
ml slice culture medium (either control or experimental)
and were pre-incubated at 37 °C in 95% O2/5% CO2 in a
6-well plate. Control medium contained 50% minimal
essential medium with Earle’s salts, 25% horse serum, 25%
Hank’s balanced salts solution, 25 mM HEPES, 2 mM
L-glutamine, and 6.5mg/ml glucose. Experimental
medium was prepared by adding nanoparticles at a con-
centration of 5mg/ml to the aforementioned control
medium. Every 24 h, cell culture inserts were transferred
to a new 6-well plate which was pre-incubated at 37 °C in
95% O2/5% CO2 with control or experimental medium, as
described above. Imaging and analysis of Purkinje neuron
cholesterol content was performed after 96 total hours of
incubation. In all cases, wild-type and NPC samples were
matched so that slices were prepared on the same day and
using the same reagents.
Stereotaxic mouse ICV bolus delivery
Stereotaxic administration of nanoparticles into the right
lateral ventricle via an intracerebral ventricular (ICV) in-
jection was performed on mice under vaporized isoflur-
ane anesthesia according to IACUC guidelines. Six- to
7-week-old mice received a single ICV bolus injection of
sHDL or vehicle using established protocols [25, 27].
Each anesthetized mouse received a small scalp incision
to expose the skull, and a small burr hole was drilled
relative to Bregma suture: anterior-posterior + 0.3 mm,
medio-lateral − 1.0 mm. A beveled needle (7758-04,
Hamilton, Reno, NV) connected to a 10-μL syringe
(7653-01, Hamilton, Reno, NV) was placed dorso-ventral
− 3.0 mm at a rate of 1 mm/s. A 3-min wait was allotted
for the brain to seal around the needle and prevent
backflow of treatment around the injection site. A total
of 10 μL vehicle or sHDL at a concentration of 100mg/
ml was delivered at an infusion rate of 0.5 μL/s using an
injection pump (UMC4, World Precision Instruments,
Inc., Sarasota, FL). Five minutes after the infusion was
completed, the needle was retracted at a rate of 1 mm/s
and the incision site was sutured with synthetic non-
absorbable sutures (1011209, Henry Schein, Melville,
NY). Mice were recovered in a temperature-controlled
environment, and following surgery, the mouse weight,
grooming activity, and home cage activity were recorded
for up to 7 days according to IACUC guidelines.
Microscopy
Epifluorescence: Filipin was imaged on a Zeiss Axio
Imager Z1 microscope with an automated stage. Cells
were focused in the green channel (wheat germ agglu-
tinin), and 16 tiled images were captured per experi-
ment. Images with ≥ 90% cell confluence were quantified
using NIH ImageJ software [25].
Confocal imaging of cells: Fluorescently labeled sHDL
particles were imaged on a Nikon A-1 confocal micro-
scope. Co-localization coefficients were calculated using
Nikon elements software (Pearson). Brightness and con-
trast were applied equally across the entire image to
both control and experimental groups using Photoshop.
Macrophages were outlined in F4/80-stained sections
of liver and area was quantified using ImageJ by an
investigator blinded to genotype and treatment.
Confocal imaging of tissue: One-week post intraventricu-
lar injection, vehicle or 5A-SM-treated mice were perfused
with saline and tissues were placed in 4% PFA overnight.
The liver and right hemisphere of the brain were embed-
ded in OCT, frozen, and cut into 10-μm-thick sections.
Sections were permeabilized (0.1% triton/10% NGS/1%
BSA in PBS) for 30min and placed into blocking buffer
(10% NGS/1% BSA in PBS) for 60min. Sections were
placed in primary antibody overnight at 4 °C, washed three
times in PBS for 5min, then incubated in secondary anti-
body for 1 h at room temperature. Sections were stained
with filipin and imaged on a Nikon A-1 confocal micro-
scope. Purkinje neuron soma were defined using a
calbindin-DK28 antibody, and filipin was quantified using
ImageJ.
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Stimulated Raman scattering (SRS) microscopy: Cell
monolayers were imaged at 2845 cm−1 Raman shift wave-
number to generate a greyscale image channel. Images ac-
quired at the 2845 cm−1 are chemically selective for lipids,
stimulating vibrational resonance of the CH2 symmetric
stretching mode [28]. Individual fields of view (FOVs) for
lipid quantification were generated and quantified using a
two-layer automated thresholding method to avoid selec-
tion bias. Over a full 2mm× 2mm SRS image, a 250
pixel × 250 pixel sliding window with 100-pixel step size
was used to detect FOVs with greater than 90% cellular
confluence. Mean background pixel intensity values for
each image were used to set the FOV threshold for back-
ground (i.e., media) and foreground (i.e., cells). Only FOVs
with a foreground/background ratio greater than 90% were
included for lipid quantification. After selection of FOVs, a
second thresholding procedure was used to segment intra-
cellular lipid droplets, which have high 2845 cm−1 SRS
signal compared to the remainder of the intracellular con-
tents. For each FOV, a ratio between the area of intracellu-
lar lipid to total intracellular space was calculated and
normalized to the number of cells within each image.
Amplex Red
The Amplex® Red Cholesterol Assay Kit A12216 (Invi-
trogen) was used to quantify total free cholesterol fol-
lowing the manufacturer’s instructions.
Cell death
Cell viability was assessed using Promega CellTiter 96
Aqueous One Solution cell proliferation colometric assay
(G3580). Briefly, Niemann–Pick C cells were cultured in
96-well plates at 10,000 cells per well for 24 h, washed
3× with PBS, and treated as indicated with compounds
diluted in media for 24 h. Cells were washed 3× with
PBS and re-suspended in media supplemented with Pro-
mega CellTiter 96 reagent (20 μl reagent per 100 μl of
media). After 45-min incubation at 37 °C, absorbance
was read at 490 nm using a microplate reader. Each
treatment was performed in triplicate, and the average
absorbance reading of non-treated (Veh) cells was set to
100%. The percent viability was determined by dividing
the average absorbance of treated over non-treated cells
and multiplying by 100.
Sphingomyelin loading
C6-NBD sphingomyelin was dissolved in 100% ethanol
to make a 10mM stock solution. Cells were treated with
40 μM C6-NBD sphingomyelin in cell culture media
overnight. The following day (t = 0), wells were briefly
washed 2× with PBS and fresh media without C6-NBD
sphingomyelin was added. At t = 0 and t = 24 h, cells
were treated with fresh media containing vehicle (saline)
or 5A-SM.
Radioactive cholesterol efflux assay
Preparation of [3H] cholesteryl linoleate-loaded acLDL
Cholesteryl [1,2,6,7-3H(N)] linoleate (60 Ci/mmol) was
loaded into acetylated human LDL (acLDL) according to
procedure adapted from Brown et al. [29]. Briefly, 30 μCi
(0.5 nmol) cholesteryl [1,2,6,7-3H(N)] linoleate in tolu-
ene was evaporated to dryness under a stream of nitro-
gen gas. Then, a thin film of cholesteryl [1,2,6,7-3H(N)]
linoleate was dissolved in 10 μl DMSO followed by the
addition of 100 μl acLDL (5 mg of protein/ml). The mix-
ture was incubated for 2 h at 37 °C with gentle shaking
to incorporate cholesteryl [1,2,6,7-3H(N)] linoleate into
acLDL and then dialyzed at 4 °C against 20 mM Tris/
HCl, 0.3 mM EDTA, 0.15M NaCl, pH 7.4 using 3.5K
MWCO slide-A-Lyzer mini device (ThermoFisher 88,
400). Cholesteryl [1,2,6,7-3H(N)] linoleate-acLDL mix-
ture routinely contained 90–95% of starting radioactivity
as determined by scintillation counting before and after
dialysis.
Cholesterol efflux assay
Niemann–Pick C fibroblast cells were grown in culture
media until confluency. On day 1, 75,000 cells were plated
in 24-well plates and grown for 24 h in 0.5-ml culture
media. On day 2, cells were washed with PBS, pH 7.4, 1×
at room temperature and grown overnight in media con-
taining lipoprotein-deficient serum (10% v/v) in DMEM
to upregulate LDL receptors. On day 3, cells were washed
with PBS, pH 7.4, 2×, and labeled with cholesteryl [1,2,6,7-
3H(N)] linoleate-acLDL for 24 h in DMEM (no phenol
red)/BSA (1mg/ml)/P-S media (0.5ml) containing 1 μCi
of [3H] cholesteryl linoleate per 1-ml media. On day 4, la-
beled cells were washed with PBS, pH 7.4, 3×, to remove
cholesteryl [1,2,6,7-3H(N)] linoleate not taken up by cells.
Radioactive cholesterol was effluxed from cells for 24 h
using vehicle (media), 5A peptide (0.75mg/ml), 5A-SM
HDL, 5A-DMPC, 5A-POPC (0.75mg/ml), or cyclodextrin
(1mM) diluted in DMEM/BSA/P-S. On day 5, media
from each well was transferred into separate Eppendorf
tubes and centrifuged at 3000 rpm for 10min to remove
any detached cells. The remaining cells on the plate were
lysed with 0.1% SDS/0.1M NaOH solution for 2 h at room
temperature. Radioactive counts of media and cell frac-
tions were measured separately using a Perkin Elmer li-
quid scintillation counter. Percent cholesterol effluxed
from cells was calculated by dividing media counts by the
total sum of media and cell counts and then multiplying
by 100%. Non-specific cholesterol efflux by vehicle was
subtracted from all data.
In vivo cholesterol mobilization
Total serum cholesterol concentrations from 7-week-old
Niemann–Pick C mice pre- and 2 h post-treatment with
100 mg/kg 5A-SM i.p. were analyzed enzymatically by a
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colorimetric cholesterol oxidase assay (Wako Chemicals,
Richmond, VA) using microplate reader.
Distribution of mobilized cholesterol in lipoproteins
Serum samples from Niemann–Pick C mice collected at
baseline and 2 h post-treatment with 100 mg/kg 5A-SM
i.p. were analyzed to assess the cholesterol distribution
between VLDL, LDL, and HDL lipoprotein fractions.
Separation of lipoproteins from serum was performed
on a Waters HPLC system equipped with a Superose 6,
10/300 GL column (GE Healthcare, Piscataway, NJ) and
a fraction collector. Serum samples were injected onto the
HPLC and eluted with saline solution pH 7.4 at 1ml/min.
Eluent fractions containing different lipoproteins were
post-column reacted in the HPLC with an enzymatic solu-
tion for total cholesterol detection [30].
Radioactive sphingomyelin efflux assay
Cells (40,000 cells/well) were cultured for 24 h in 24-
well plates and then incubated with 1 μCi (80 Ci/mmol)
sphingomyelin [choline methyl-3H] per 1-ml media.
After 24 h, cells were washed with PBS, pH 7.4, 3×,
followed by the treatment with vehicle or 0.75 mg/ml
5A-SM in culture media. Radioactivity in media and
cells was counted using a PerkinElmer scintillation
counter. Percent sphingomyelin effluxed from cells was
calculated by dividing media counts by the total sum of
media and cell counts and then multiplying this number
by 100%. Non-specific sphingomyelin efflux by vehicle
was subtracted from all data.
Serum analysis
Whole blood was collected and allowed to clot for 5 min
in BD microtainer® SST gold cap tubes (365967). Tubes
were centrifuged for 5 min at 3000×g to remove the clot.
Liver enzymes were blindly analyzed by the University of
Michigan In-Vivo Animal Core.
Statistics
Significance (p < 0.05) was determined by Graphpad
Prism 7.0. Figure legends indicate when unpaired Stu-
dent’s two-tailed t test, one-way or two-way ANOVA
with Tukey, or Bonferroni post hoc analysis were used.
All error bars are s.e.m. Graphpad outlier analysis was
used to remove one outlier per group for Purkinje
neuron filipin quantification.
Results
Design and synthesis of sHDL nanoparticles
ApoA1 enwraps lipids into 10–12-nm nanodiscs to form
endogenous HDL [31]. These particles contain a hetero-
geneous mixture of saturated and unsaturated phospho-
lipids, with each lipid having distinct cholesterol binding
properties [32]. Relative to full-length ApoA1 protein, use
of synthetic ApoA1 mimetic peptide is beneficial due to the
ease of manufacturing, enhanced quality control, and lower
cost [12]. We utilized the ApoA1 mimetic peptide 5A,
which is designed to maximize cholesterol efflux by ABCA1
[22]. Using phospholipids with differing affinities for chol-
esterol [33], we developed a panel of sHDLs containing
various 5A:lipid formulations, including sphingomyelin
(SM), a saturated phospholipid (DMPC, 1,2-dimyristoyl-sn-
glycero-3-phosphocholine), or an unsaturated phospholipid
(POPC, 1-palmitoyl-2-oleoyl-glycero-3-phosphocholine).
All sHDLs (5A-SM, 5A-POPC, and 5A-DMPC at 1:1.5
wt/wt ratio) were prepared by co-lyophilization and
thermocycling (Fig. 1a) [14]. The lyophilization and ther-
mocycling processes are highly efficient, and we detected
little difference in the expected and actual ratios of pep-
tide to lipid (Additional file 1: Table S1). sHDL particles
had an average diameter of 10–12 nm (5A-SM and 5A-
DMPC) as determined by dynamic light scattering (Fig.
1b). Hydrophobic uncomplexed lipids spontaneously
form ≥ 100 nm liposomes. Large liposomes were not de-
tected by dynamic light scattering (data not shown) indi-
cating a highly efficient incorporation of lipids into
sHDL. sHDLs also exhibited the expected size and disc-
like morphology by transmission electron microscopy
(Fig. 1c). sHDL “stacking” by transmission electron mi-
croscopy is likely an artifact of sample preparation since
dynamic light scattering revealed monomeric sHDL in
solution.
sHDLs rescue cholesterol storage in Niemann–Pick type C
fibroblasts
To assess the activity of sHDL on Niemann–Pick type C
patient cells, we used the fluorescent dye filipin to label
accumulated unesterified cholesterol. We analyzed filipin
staining intensity in Niemann–Pick C fibroblasts following
treatment with vehicle, 5A peptide alone, or sHDLs com-
posed of 5A-POPC, 5A-SM, or 5A-DMPC. Treatment
with 5A peptide alone did not significantly alter filipin in-
tensity over 48 h (Fig. 2a, b). In contrast, both 5A-SM and
5A-DMPC significantly rescued stored cholesterol in a
dose- and time-dependent manner in three independent
lines of Niemann–Pick C primary fibroblasts (Fig. 2a, b,
Additional file 1: Figure S1a). sHDL composed of 5A-
POPC yielded a more modest and less consistent rescue,
demonstrating that lipid composition impacts biological
activity. The beneficial effects of sHDL treatment were
confirmed using an amplex red assay to measure total
cellular cholesterol (Fig. 2c). Assessment of cell viability
following treatment showed no significant changes, except
for mild toxicity from 5A-DMPC (Additional file 1: Figure
S1b). Taken together, these studies demonstrate sHDL
activity and tolerability, and given the investigational new
drug status of 5A-SM, prompted further analysis of SM-
containing sHDLs.
Schultz et al. BMC Medicine          (2019) 17:200 Page 6 of 18
Although the lipid content of sHDL is a strong deter-
minant of cholesterol efflux, the composition of the
ApoA1 mimetic peptide is also important for sHDL
function [17]. In order to investigate the impact of the
ApoA1 mimetic peptide on sHDL’s ability to reduce cel-
lular cholesterol storage, nanoparticles were prepared
with another peptide, 22A [34, 35]. Both 5A and 22A
peptides have no sequence homology with endogenous
ApoA1 and were optimized differently: 5A peptide was
selected to maximally efflux cholesterol by ABCA1,
while 22A peptide was selected to maximize cholesterol
esterification within sHDLs in plasma [16, 22, 35].
Raising the lipid to peptide ratio increases sHDL’s size
and its capacity to accept cholesterol [15]. It is generally
believed that larger sHDL particles efflux cholesterol
through scavenger receptor B-1 (SR-B1) [36]. To exam-
ine the effect of peptide sequence and peptide to lipid
ratio on cholesterol removal, we generated a panel of
sHDLs containing 5A or 22A and various peptide to SM
ratios. Filipin analysis revealed significant cholesterol-
reducing activity of sHDLs containing 5A-SM but not
22A-SM. Moreover, we found that a 1:1.5 wt/wt ratio of
5A:SM was optimal at reducing filipin intensity (Fig. 2d).
To determine which cholesterol transporter is primarily
responsible for 5A-SM mediated removal of unesterified
cholesterol from Niemann–Pick C cells, we performed ex-
pression analysis of NPC patient fibroblasts. In contrast to
ABCG1, expression of ABCA1 and SR-B1 were readily
detected by qPCR (Additional file 1: Figure S1c). Next, we
treated primary fibroblasts with non-targeting siRNAs
(siNT), or siRNAs targeting SR-B1 (siSR-B1) or ABCA1
(siABCA1). 5A-SM efficiently rescued cholesterol storage
after treatment with either siNT or siSR-B1, but not after
treatment with siABCA1 (Fig. 2e). As siRNAs significantly
reduced expression of target genes (Additional file 1: Figure
S1d), this analysis confirmed that 5A-SM requires ABCA1
to function. Notably, increasing cholesterol content of 5A-
SM reduced its effect on clearance of unesterified choles-
terol (Fig. 2f). Consistent with this observation, incubation
with a heterogeneous pool of human plasma HDL
(HuHDL) containing nascent (cholesterol poor) and mature
(cholesterol loaded) HDL failed to reduce cellular choles-
terol levels (Fig. 2f). These data contrast the observation
that the cholesterol reducing agent 2-hydroxypropyl-beta
cyclodextrin (cyclodextrin) preloaded with cholesterol re-
mains effective at reducing unesterified cholesterol in Nie-
mann–Pick C cells [37–39], and raise that possibility that
sHDL and cyclodextrin have distinct mechanisms of action.
5A-SM induces the expression of cholesterol regulatory
genes
To more fully define the biological responses triggered
by sHDLs, we treated Niemann–Pick C fibroblasts with
increasing doses of cyclodextrin or 5A-SM and analyzed
the expression of cholesterol regulatory genes. A 48-h
treatment with cyclodextrin did not alter the expression
Fig. 1 Synthesis and characterization of sHDL nanoparticles. a A lyophilized mixture of 5A peptide and sphingomyelin (SM) was hydrated in PBS
and thermocycled to assemble sHDL particles. b, c Particle size distribution was analyzed by b dynamic light scattering for 1 mg/mL of 5A-SM,
5A-DMPC, or 5A-POPC sHDL or c transmission electron microscopy of 5A-SM, 5A-DMPC, and 5A-POPC. Scale bar = 100 nm
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of HMGCR, HMGCS1, or LDLR (Fig. 3a). This is con-
sistent with previous research showing cyclodextrin
causes a transient decrease then restoration in choles-
terol biosynthetic genes by 48 h [37, 38, 40]. In contrast,
48 h of treatment with 5A-SM or 5A-DMPC caused a
dose-dependent increase of cholesterol biosynthetic
(HMGCR, HMGCS1, SREBP) and uptake genes (LDLR)
in three independent lines of patient fibroblasts (Fig. 3a,
Additional file 1: Figure S2a, b). Additionally, expression
of the cholesterol export gene ABCA1 was significantly
decreased (Fig. 3a, Additional file 1: Figure S2a, b). To-
gether, these data suggest that sHDLs efficiently extract
cholesterol from target cells and act at different time
scales than cyclodextrin.
Treatment with 5A-SM also significantly increased the ex-
pression of NPC1 mRNA and protein (Fig. 3a, b, Additional
file 1: Figure S2c, d). This is notable since multiple groups
have shown that a subset of NPC1 missense mutants are
functional if they escape ER degradation and traffic to LE/
Lys [41, 42]. To determine whether the induction of NPC1
contributed to rescue of lipid storage, we took advantage of
the fact that the NPC1 protein is heavily glycosylated. These
glycans are modified as the protein traffics through the med-
ial Golgi, rendering them resistant to cleavage by endoglyco-
sidase H (EndoH) but maintaining sensitivity to PNGaseF.
As expected, wild-type (WT) NPC1 protein expressed in
control fibroblasts was resistant to EndoH cleavage, while
mutant NPC1 protein from patient fibroblasts was sensitive
to EndoH (Fig. 3c). Treatment with 5A-SM did not alter the
sensitivity of mutant NPC1 to digestion by EndoH, indicat-
ing that the accumulated protein did not traffic to LE/Lys
(Fig. 3c, Additional file 1: Figure S2e). We conclude that 5A-
SM removes cholesterol from patient fibroblasts without
correcting mutant NPC1 protein trafficking or function.
5A-SM enters cells through macropinocytosis and
promotes cholesterol efflux
Cholesterol is loaded into nascent HDL particles when
ApoA1 interacts with receptors such as ABCA1 at the
plasma membrane. However, a prior report indicates
that ApoA1 and ABCA1 may be endocytosed as a
complex [43]. Studies have suggested that ApoA1/
ABCA1 endocytosis is required for removal of accumu-
lated LDL-derived cholesterol from LE/Lys [43, 44]. To
determine if 5A-SM enters cells through endocytosis, we
treated Niemann–Pick C patient fibroblasts with 5A-SM
sHDLs containing the fluorescent lipophilic dye DiD
(5A-SM-DiD). Confocal imaging revealed little 5A-SM-
DiD signal on the plasma membrane, yet readily identi-
fied fluorescent signal in the cytoplasm, indicating up-
take of the 5A-SM-DiD nanoparticles (Fig. 4a). To
define the mechanism of uptake, cells were pretreated
with the macropinocytosis inhibitor amiloride [45] or
the clathrin and caveolar inhibitor dynasore, then loaded
with 5A-SM-DiD. Dynasore had little effect on 5A-SM-
DiD uptake, while amiloride significantly reduced 5A-
SM-DiD signal intensity, indicating that macropinocyto-
sis is a major route of 5A-SM-DiD endocytosis (Fig. 4a).
Notably, the lipophilic tag DiD was not covalently conju-
gated to 5A-SM; therefore, the punctate cytoplasmic pat-
tern of fluorescence could represent DiD dissociated
from the nanoparticle. To rule out this possibility, we
synthesized sHDLs containing 5A peptide covalently
conjugated to Alexa647 (5A-Alexa647) and incorporated
the lipophilic dye DiA into these particles (5A:Alexa647-
SM:DiA). After 2-h incubation, the 5A and DiA signals
strongly co-localized (Fig. 4b) indicating that the inter-
nalized 5A-SM sHDL particles remained intact inside
the cell.
Unesterified cholesterol that accumulates within Nie-
mann–Pick C cells resides in LAMP1-positive LE/Lys
[39]. To determine if 5A-SM traffics to this compart-
ment, we conducted a time course and analyzed co-
localization of 5A-SM-DiD with LAMP1 and filipin. We
observed that a fraction of 5A-SM-DiD co-localized with
LAMP1 and filipin-positive lipid storage vesicles over a
period of 2 h (Fig. 4c). At this time point, 5A-SM-DiD
did not co-localize with the recycling endosome/early
endosome marker EEA1 (Additional file 1: Figure S3),
possibly because it had already traveled past this com-
partment. Whether lysosomal/filipin-positive 5A-SM-
DiD compartments represent the primary site of sHDL
(See figure on previous page.)
Fig. 2 sHDLs require ABCA1 to remove accumulated cholesterol from Niemann–Pick C fibroblasts. a–f Primary fibroblasts homozygous for NPC1
I1061T were treated with various sHDL formulations. a, b Accumulation of unesterified cholesterol was visualized by filipin staining (a) following 48-h
treatment with increasing doses (representative images of 0.75mg/ml) of vehicle (Veh), 5A peptide, 5A-POPC, 5A-SM, and 5A-DMPC (quantified below)
or (b) with 0.75mg/ml sHDL at various time points. c Effects of 48-h treatment with sHDL (0.75mg/ml), 5A peptide, or vehicle (Veh) on total cellular
cholesterol were measured using the Amplex Red assay. d The ratio of 5A or 22A peptide to sphingomyelin (SM) was altered during synthesis and the
effect of peptide: SM ratio on cholesterol removal was determined by filipin staining (48-h treatment). e Cells were treated for two consecutive days
with the following siRNAs: non-targeting (NT), ABCA1, or SR-B1, and concurrently treated with vehicle (Veh) or 5A-SM. Cholesterol storage was
determined by filipin staining. f Cells were treated with cyclodextrin (Cyclo), 5A-SM, or 5A-SM preloaded with increasing amount of cholesterol content
(5–20% total lipid weight), or human HDL (HuHDL). Cholesterol storage was assessed by filipin staining 48 h after treatment. Data are mean ± s.e.m.
from (a, b, e) three, (c) five, (d) 5–8, or (f) 4–6 independent experiments. n.s., not significant, *p≤ .05, **p≤ .01, ***p≤ .001, ****p≤ .0001 by a, b two-
way ANOVA with Bonferroni post hoc test (F, df = (a) 33.53, df = 4; (b) 32.88, 4), c–f one-way ANOVA with Tukey post hoc test (F, df = (c) 13.98, 4; (d)
6.96, 8; (e) 22.5, 6; (f) 6.94, 5). a Dash lines indicate plasma membrane, scale bar = 20 μm
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Fig. 3 sHDLs modulate cholesterol regulatory genes. a Primary fibroblasts homozygous for NPC1 I1061T were treated with vehicle (Veh), cyclodextrin
(cyclo), or 5A-SM at the indicated concentrations for 48 h. HMGCR, HMGCS1, ABCA1, LDLR, SREBP, or NPC1 mRNA expression was analyzed by qPCR. b,
c NPC1 protein in control (CTRL) and NPC1 I1061T (NPC) fibroblasts was analyzed by b western blot (quantified at right) or c digested with
endoglycosidase H (E), PNGase F (P), or not treated (NT) and analyzed by western blot. Data are mean ± s.e.m. from three independent experiments.
n.s., not significant, *p≤ .05, **p≤ .01, ***p≤ .001, ****p≤ .0001 relative to Veh by a one-way ANOVA with Tukey post hoc test (F, df = (HMGCR) 27.43,
df = 5; (HMGCS1) 24.75, 5; (ABCA1) 43.54, 5; (LDLR) 9.4, 5; (SREBP) 7.0, 5; (NPC1) 12.41, 4. b Student’s t test t = 3.83, df = 2
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action requires further investigation, and it remains pos-
sible that sHDLs act at other intracellular sites. In either
case, we sought to confirm that sHDL uptake was ac-
companied by efflux of stored cholesterol. To accom-
plish this, patient fibroblasts were loaded and then
equilibrated with [3H] cholesteryl linoleate bound to
LDL. We treated cells with 5A or 5A-SM for 24 h and
then measured intracellular and extracellular
[3H]cholesterol. Incubation with 5A peptide alone re-
sulted in ~ 20% efflux of radiolabeled LDL-derived
cholesterol to medium (Fig. 4d). Notably, pre-formed
5A-SM sHDL particles were much more effective at
effluxing LDL [3H] cholesterol than 5A alone, result-
ing in release of ~ 60% of labeled cholesterol into the
media. In contrast, 24-h treatment with 1 mM cyclo-
dextrin resulted in a modest 6.2% ± 2.7 efflux of LDL-
derived cholesterol at this early time point. This is in
line with previous data showing that cyclodextrin ex-
tracts cholesterol from the plasma membrane and can
mobilize it from intracellular stores [39, 40, 46].
5A-SM mobilizes cholesterol and ameliorates phenotypes
in Niemann–Pick C mice
Based on the significant rescue of cholesterol storage ob-
served in vitro, we sought to determine the extent to
which administration of sHDLs benefit gene targeted mice
homozygous for the Npc1 I1061T allele (Niemann–Pick C
mice). These mice contain the most common Niemann–
Pick C disease-causing mutation (I1061T). Starting at 7
weeks of age, these mice develop robust, progressive phe-
notypes including cholesterol accumulation, Purkinje
neuron loss, motor impairment, and premature death by
13 weeks of age [24]. Niemann–Pick C mouse serum
collected pre- and 2 h post-intraperitoneal (i.p.) injection
of 5A-SM established that treatment significantly in-
creased serum cholesterol content (Fig. 5a). High-
performance liquid chromatography (HPLC) was used to
identify cholesterol-containing fractions (VLDL, LDL, or
HDL). Serum cholesterol was distributed in all lipoprotein
fractions 2 h post 5A-SM injection, with LDL and VLDL
particles containing the most cholesterol (Fig. 5b). This is
a typical lipoprotein profile after sHDL administration,
where immediate HDL-cholesterol elevation is followed
by transient LDL/VLDL-cholesterol elevation while chol-
esterol is metabolized, returning to baseline 24 h post-
treatment [14, 15, 19]. Consistent with data showing chol-
esterol mobilization into the serum, a single injection of
5A-SM significantly upregulated the cholesterol biosyn-
thetic gene HMGCS in the liver (Fig. 5c), similar to our
findings in patient fibroblasts (Fig. 3a). These data provide
evidence of target engagement after in vivo administration
of sHDL to Niemann–Pick C mice.
To determine whether Niemann–Pick C mice showed
benefits from sHDL administration, we initially focused
on peripheral disease manifestations that might be re-
sponsive to i.p. administration. Niemann–Pick C mice
exhibit significantly elevated serum bilirubin levels, di-
minished body weight, and liver macrophage activation.
We analyzed total bilirubin levels in 7-week-old WT and
Niemann–Pick C mice 48 h after a single injection of ve-
hicle or 5A-SM. sHDL administration rescued bilirubin
levels in Niemann–Pick C mice without altering them in
WT littermates (Fig. 5d). Niemann–Pick C mice also ex-
hibit progressive body weight loss as they age [24]. To
determine effects on this disease manifestation, 5A-SM
or vehicle was injected i.p. three times per week from 7
to 11 weeks of age, and the change in weight was calcu-
lated for each mouse for the duration of the treatment
trial. WT mice treated with either vehicle or 5A-SM
gained ~ 2 g during the treatment period, whereas ve-
hicle treated Niemann–Pick C mice failed to gain body
weight. In contrast, Niemann–Pick C mice treated with
5A-SM exhibited a significant rescue of body weight,
gaining as much weight as WT controls (Fig. 5e). Ad-
ministration of 5A-SM also significantly reduced liver
macrophage size in Niemann–Pick C mice (Fig. 5f).
While i.p. administration of sHDL showed significant
benefits for these peripheral phenotypes, it did not cor-
rect motor phenotypes (Additional file 1: Figure S4a),
suggesting poor blood–brain barrier penetration.
The Niemann–Pick C mouse motor phenotypes are
driven, in part, by loss of cholesterol-laden cerebellar
(See figure on previous page.)
Fig. 4 5A-SM is endocytosed and increases cholesterol efflux. a–d NPC1 I1061T fibroblasts were treated with the indicated sHDL for a–c 2 or d
24 h. a Cells were pre-treated with dynasore (80 μM), amiloride (1 mM), or vehicle (Veh) for 30 min and then incubated with fresh media
containing 5A-SM-DiD plus dynasore, amiloride, or vehicle for 2 h. Plasma membranes are outlined with dashed lines. 5A-SM-DiD (red) intensity is
quantified at the right. b Cells were treated with sHDL composed of 5A-Alexa647 (green) and DiA (red) incorporated into the SM fraction.
Following 2-h incubation, cells were labeled with NucStain (blue) and imaged by confocal microscopy. Pearson co-localization coefficient = 0.75 ±
0.01. c Cells were incubated with 5A-SM-DiD (red) for 1, 1.5, and 2 h, fixed, stained for LAMP1 (green) and filipin (blue), and imaged by confocal
microscopy. Representative images from 2 h post-treatment. Pearson co-localization coefficient quantified below. d Cells were pre-treated for 24 h
with acetylated LDL containing [3H] cholesteryl linoleate to specifically deliver cargo to the lysosomal compartment. Following 24-h equilibration,
cells were treated for 24 h with 0.75 mg/ml 5A peptide or 5A-SM. Radioactivity in media and cell fractions was determined by liquid scintillation
counting, and values were normalized to vehicle treated group. Data are mean ± s.e.m. from three independent experiments. n.s., not significant,
*p≤ .05, **p≤ .01, ****p≤ .0001 by a one-way ANOVA with Tukey post hoc test relative to Veh or 5A (F = 10.74, df = 2); c two-way ANOVA with
Bonferroni post hoc test (F, df = 23.63, 2). d Student’s t test t = 13.09, df = 4. Scale bar = a 12 μm, b 20 μm, c 10 μm
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Purkinje neurons [47, 48]. To determine whether sHDLs
could rescue cholesterol storage in neurons, we treated
cultured cerebellar slices from adult WT and Niemann–
Pick C mice with vehicle or 5A-SM for 4 days. Slices
were fixed and co-labeled for Purkinje neurons (calbin-
din) and cholesterol (filipin). Confocal imaging demon-
strated that treatment of Niemann–Pick C brain slices
significantly reduced cholesterol storage in Purkinje neu-
rons (Fig. 5g and Additional file 1: Figure S4b). This
finding demonstrates that sHDLs are active on CNS tar-
get cells if they gain access to the brain. To directly test
CNS activity, we performed intraventricular injections in
6–7week-old Niemann–Pick C mice with vehicle or 5A-
SM containing the fluorescent dye DiD (5A-SM-DiD), a
manipulation that was well tolerated. One week post-
injection, 5A-SM-DiD signal localized to the cerebellum,
brain stem, cortex, and hippocampus (Additional file 1: Fig-
ure S5). In the cerebellum, the fluorescent signal from DiD
localized predominantly to astrocytes and, to a lesser ex-
tent, microglia at this time point (Additional file 1: Figure
S6b, c). We calculated Purkinje neuron soma size as a po-
tential indicator of in vivo toxicity of 5A-SM 1 week post
injection. Suggesting little toxicity, Purkinje neuron soma
size was unchanged with 5A-SM treatment (WT+Veh,
185 ± 44; NPC+Veh, 207 ± 57; and NPC+ 5A-SM, 206 ±
61 pixels). One week post-injection, we observed significant
reduction of cholesterol accumulation in Purkinje neurons
in Niemann–Pick C mice treated with sHDL (Fig. 5h).
5A-SM reduces accumulated sphingomyelin in Niemann–
Pick A fibroblasts
Both cholesterol and sphingomyelin utilize the ABCA1
transporter to efflux from cells into an HDL acceptor
[49]. These two lipids physically interact and commonly
traffic together [50]. This suggested that sHDL might be
effective at rescuing aberrant storage of sphingomyelin
as well as cholesterol. Sphingomyelin is normally metab-
olized by the lysosomal enzyme acid sphingomyelinase,
and loss-of-function mutations in the encoding gene re-
sult in sphingomyelin accumulation, causing Niemann–
Pick disease types A and B [51].
To determine whether sHDL was capable of removing
stored sphingomyelin from cells, Niemann–Pick A and con-
trol primary fibroblasts were loaded with [3H] sphingomye-
lin for 24 h and then treated with 5A-SM. After 24 h, 5A-
SM promoted the efflux of twice as much [3H] sphingomye-
lin from Niemann–Pick A cells than control cells (Fig. 6a).
To confirm this observation, Niemann–Pick A fibroblasts
were loaded overnight with fluorescent NBD-
sphingomyelin. Cells were then treated with vehicle, cyclo-
dextrin, or 5A-SM for 48 h (Fig. 6b). As expected, control
cells metabolized NBD-sphingomyelin and had little signal,
while Niemann–Pick A cells showed marked cytoplasmic
accumulation. Remarkably, 5A-SM significantly reduced
NBD-sphingomyelin storage in Niemann–Pick A fibroblasts.
In contrast, cyclodextrin treatment was ineffective, consist-
ent with previous work in other sphingolipidoses [52].
The addition of exogenous sphingomyelin can alter
membrane dynamics and impact downstream protein func-
tion [53, 54]. Therefore, we sought to determine effects of
5A-SM on endogenous lipids stored in Niemann–Pick A
cells. To detect total lipids in a live, unfixed state, we uti-
lized stimulated Raman scattering (SRS) microscopy. This
SRS system generates virtual histology images that are use-
ful for a variety of applications, including the clinical setting
[55]. SRS utilizes an excitation and pump beam at the Ra-
man wave number for CH2 bonds to rapidly image total
lipids in biological samples. Since sphingomyelin contains
extensive CH2 bonds, we developed SRS cell plating, im-
aging, and analysis procedures for Niemann–Pick A fibro-
blasts. SRS imaging demonstrated that Niemann–Pick A
fibroblasts had double the lipid signal intensity compared
(See figure on previous page.)
Fig. 5 5A-SM mobilizes cholesterol in vivo and ameliorates disease phenotypes. a Serum cholesterol from 7-week-old Npc1 I1061T homozygous
mice pre- and 2 h post-treatment with 100 mg/kg 5A-SM, i.p. b Pre- (dashed line) and 2 h post-treatment (solid line) serum was fractionated by
HPLC, and cholesterol was quantified by cholesterol oxidase assay. VLDL, LDL, and HDL fractions are indicated by arrows. c, d Seven-week-old
wild-type (WT) and Npc1 I1061T homozygous (NPC) mice were injected i.p. with vehicle (Veh) or 100 mg/kg 5A-SM. 48 h later, c liver HMGCS
transcript levels and d total serum bilirubin were analyzed. e WT and Npc1 I1061T mice were injected i.p. with vehicle (Veh) or 100 mg/kg 5A-SM
three times per week from 7 to 11 weeks of age. The change in weight of each mouse from week 7 (t = 0) to week 11 (t = 4) was quantified. f
Seven-week-old WT and NPC mice were injected with Veh or 100 mg/kg 5A-SM three times per week for 2 weeks. At 9 weeks of age livers were
stained for macrophages using F4/80 (green) and DNA Hoechst (blue). Macrophage area is quantified at right. Scale bar = 50 μm. Violin plot
shows median (dashed line), 25% and 75% (dotted lines), and probability density (thickness). g Brain slices from 8-week-old Npc1 I1061T mice
were incubated with vehicle (Veh) or 5 mg/ml 5A-SM for 4 days, and filipin levels in Purkinje neuron soma were quantified (see also Additional
file 1: Figure S4b). h Six- to 7-week-old WT and Npc1 I1061T mice received intraventricular injections with vehicle (Veh) or 5A-SM-DiD. N: WT = 4,
NPC Veh = 5, NPC 5A-SM = 4 mice. One-week later, cholesterol levels in Purkinje neuron soma (green) were analyzed by filipin (blue) staining.
Dashed lines indicate Purkinje neuron soma (also see Additional file 1: Figure S6a). Scale bar = 50 μm. Data quantified at right. Data are mean ±
s.e.m. from a, b, c three; d genotype and treatment: number of mice, WT + Veh = 5, WT + 5A-SM = 3, NPC + Veh = 4, NPC + 5A-SM = 7; e genotype
and treatment: number of mice at 9 weeks and 11 weeks, WT + Veh: 13 and 8, WT + 5A-SM: 9 and 8, NPC + Veh: 6, NPC + 5A-SM: 12 and 10 mice;
f genotype and treatment: number of mice, cells, WT + Veh: 4, 301, NPC + Veh: 4, 514, NPC + 5A-SM: 3, 373 (g) WT = 93, NPC Veh = 143, NPC + 5A-
SM = 116 cells. *p≤ .05, **p≤ .01, ***p≤ .001, ****p≤ .0001. a, c Student’s t test (t = (a) 6.375, (c) 5.23); d, f, g, h one-way ANOVA with Tukey post
hoc test (F, df = (d) 13.28, 3; (f) 368.1, 2 (g) 38.89, 2; (h) 108.3, 2); e two-way ANOVA with Bonferroni post hoc test (F, df = 7.12, 2)
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to control cells (Fig. 6c). Treatment of Niemann–Pick A fi-
broblasts with 5A-SM rescued this lipid storage, whereas
treatment with cyclodextrin did not. Collectively, these data
show that 5A-SM is effective at reducing sphingomyelin
storage in Niemann–Pick A cells and suggest that sHDL
nanoparticles may be therapeutically beneficial for the fam-
ily of Niemann–Pick diseases.
Discussion
We describe an innovative approach to ameliorating lipid
storage in the Niemann–Pick family of diseases by harnes-
sing the activity of the body’s endogenous cholesterol scav-
enging particle, HDL. The sHDL particles characterized
here potently remove stored cholesterol from Niemann–
Pick C fibroblasts (Fig. 2) and neurons (Fig. 5f). The parti-
cles show evidence of cholesterol target engagement and
rescue disease phenotypes when administered to Nie-
mann–Pick C mice (Fig. 5). The 10–12 nm sHDL nano-
discs are generated at high purity by assembling peptide-
lipid nanoparticles by a co-lyophilization and thermocy-
cling process (Fig. 1). Notably, the degree of cholesterol re-
moval was affected by altering the constituent ApoA1
mimetic peptide, lipid, and peptide to lipid ratio (Fig. 2),
demonstrating that sHDLs provide a flexible platform that
can be tuned to adjust therapeutic potency. Moreover, our
observation that the sHDL that rescues cholesterol storage
in type C disease also rescues sphingolipid storage in type
A disease (Fig. 6) raises the possibility that alternative sHDL
Fig. 6 5A-SM removes sphingomyelin from Niemann–Pick type A fibroblasts. a Control (CTRL) and Niemann–Pick A (NPA) primary fibroblasts
were incubated with [3H] sphingomyelin for 24 h, followed by treatment with 0.75 mg/ml 5A-SM or vehicle (Veh). Radioactivity in media and cell
fractions was determined by liquid scintillation counting. b CTRL and NPA primary fibroblasts were loaded with NBD-sphingomyelin, then treated
for 48 h with vehicle (Veh), cyclodextrin (Cyclo), or 0.75 mg/ml 5A-SM. NBD-sphingomyelin intensity quantified at right. Scale bar = 20 μm. c SRS
microscopy was used to image total endogenous lipids in CTRL and NPA cells with the indicated treatments. Quantified at right. Scale bar =
20 μm. Data are mean ± s.e.m. from a, b, c three; *p≤ .05, ***p≤ .001, ****p≤ .0001. a Student’s t test (t = 6.04); b, c one-way ANOVA with Tukey
post hoc test (F, df = (b) 55.57, 3; (c) 8.285, 3)
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compositions may be beneficial for additional lipid storage
disorders. The initial in vivo analyses presented here pro-
vide a proof of concept of activity for a single sHDL formu-
lation, 5A-SM, at limited points. 5A-SM treatment of
Niemann–Pick C mice induces cholesterol mobilization
from the liver (increased HMGCS expression, Fig. 5c), in-
creases serum cholesterol (Fig. 5a), and reduces liver in-
flammation (Fig. 5f). These data set the stage for additional
analyses in Niemann–Pick animal models, including com-
parisons with other therapies currently administered to pa-
tients or in clinical trial. Future analyses are also needed to
determine the extent to which optimized sHDL treatment
regimens impact lysosomal cholesterol and sphingolipid
storage in liver and normalize oxysterol biomarkers.
Prior studies have established that Niemann–Pick type
C cells have normal ApoA1 receptor binding, endocytosis,
and re-secretion [56, 57], yet Niemann–Pick patients have
reduced serum HDL levels [56, 58–62] that likely worsen
lipid storage. Previous reports have also demonstrated that
Niemann–Pick type C cells are defective in loading chol-
esterol into ApoA1 [56, 57, 63]. Similarly, we noted that
ApoA1 mimetic peptides are not sufficient for reducing
Niemann–Pick C cholesterol storage (Fig. 2a, b). Our
strategy bypassed the HDL formation deficiencies in dis-
ease by utilizing an investigational new drug, 5A-SM
sHDL, that exhibits no significant cellular toxicity. The ac-
tivity of alternative sHDL formulations will be the subject
of future research. Additionally, the extent to which in-
corporation of ApoE rather than ApoA1 mimetic peptides
and the addition of brain targeting peptides enhance
therapeutic efficacy in the CNS remain to be defined.
While the rescue of cholesterol storage from mutant fi-
broblasts required expression of ABCA1 (Fig. 2e), fluores-
cently labeled sHDLs readily entered cells by
macropinocytosis (Fig. 4a). The lipid and peptide constitu-
ents of the nanoparticles remained tightly associated within
cells (Fig. 4b, c), with some trafficking to LAMP1 and filipin
staining vesicles (Fig. 4c). Other intracellular sHDLs
remained outside these lipid storage vesicles, and the pre-
cise location of cholesterol loading remains to be deter-
mined. In contrast to LDL, there is still incomplete
understanding of HDL endocytosis and subcellular traffick-
ing [64]. Interestingly, multiple intracellular pools of HDL
have been described. After endocytosis, HDL can be re-
secreted, sent to the lysosome, or trafficked to the Golgi be-
fore re-secretion [64–66]. The location of the subcellular
pools of HDL is still being described and is likely cell type
dependent. Although we were not able to define where all
of the 5A-SM localized within cells, treatment with sHDLs
did trigger cholesterol efflux (Fig. 4d), a finding that may re-
flect release of cholesterol-laden nanoparticles and/or en-
hanced lysosomal exocytosis.
The identification of therapeutic rescue of lipid storage
in Niemann–Pick type A cells by sHDL was greatly
facilitated by SRS microscopy (Fig. 6c). This technique
was used to circumvent challenges associated with label-
ing endogenous sphingolipids and shortcomings of ap-
plying exogenous sphingolipids to study intracellular
trafficking. We were not able to identify the accumulated
lipid species by current technology and cannot exclude
the possibility that sphingomyelin correction is a conse-
quence of cholesterol removal. However, this seems un-
likely as treatment with the cholesterol-removing agent
cyclodextrin did not alter sphingomyelin accumulation
or lipid content in Niemann–Pick type A cells (Fig. 6b,
c). Notably, limited techniques allow live cell imaging of
endogenous lipids. While SRS cannot currently delineate
lipid subspecies, we anticipate that continued develop-
ment of this technology will enable this process. More-
over, the robust rescue of lipid storage in Niemann–Pick
type A cells, along with the amelioration of peripheral
phenotypes in Niemann–Pick C mice following i.p. ad-
ministration, is particularly encouraging in the context
of Niemann–Pick type B. Niemann–Pick B is character-
ized by peripheral organ system phenotypes, but not
CNS involvement. Even with the successful removal of
sphingomyelin in Niemann–Pick A cells by 5A-SM, fu-
ture research is needed to establish the optimal sHDL
formulation for removing stored lipids in this disorder.
Conclusion
Our study demonstrates a proof of concept that sHDL
significantly reduce lipid storage in both Niemann–Pick
C and A. Future work will assess the long-term effects of
sHDL in NPC and NPA/NPB mouse models. Consider-
ing the safety of sHDL in clinical trials, correction of
peripheral phenotypes would justify testing large animals
and perhaps patients with these disorders. As such, our
data suggest that 5A-SM or other sHDLs may be thera-
peutically beneficial for patients with Niemann–Pick dis-
eases and possibly other lysosomal storage disorders.
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